It is important to note that TLR4/NF-κB signaling strengthens the fibrogenic pathway of TGF-β (46), and its suppression is considered a therapeutic target in liver fibrosis (13, 25, 47). The gene discussed is NFKB1; the disease is Hepatic fibrosis.